On May 6, 2024, Cellectis S.A., closed the transaction. As the result of the transaction, AstraZeneca PLC, now owns approximately 44% of the share capital and 30% of the voting rights of the company.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,561 GBX | -0.31% | +1.35% | +18.60% |
Jun. 10 | European Equities Close Lower in Monday Trading Following Far Right Gains in EU Elections | MT |
Jun. 10 | UK Stocks Join Europe Retreat Ahead of US Fed Rate Decision | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
12,561 GBX | -0.31% | +1.35% | 249B | ||
2.2 EUR | -2.87% | -7.17% | 243M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.60% | 249B | |
+48.39% | 779B | |
-6.13% | 354B | |
+20.61% | 333B | |
+10.00% | 301B | |
-1.88% | 216B | |
+11.36% | 214B | |
+5.80% | 163B | |
-2.50% | 159B | |
+1.35% | 121B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- Cellectis S.A. announced that it has received $140 million in funding from AstraZeneca PLC